作者：Sargin G
翻译：赵金霞
摘要
背景：由于中性粒细胞、血小板和淋巴细胞的炎症变化，中性粒细胞与淋巴细胞比率（NLR）和血小板与淋巴细胞比率（PLR）可作为炎症标志物和疾病活动性的指标。本研究旨在探讨应用利妥昔单抗治疗的RA患者NLR、PLR比值与疾病活动性的关系。
方法：本研究纳入38例RA患者（男性8例，女性30例，平均年龄56.8±11.8岁）和30例健康对照。对RA患者应用利妥昔单抗治疗前后的疾病活动度评分（DAS28-ESR）、淋巴细胞、中性粒细胞、血小板计数、ESR、C反应蛋白（CRP）、PLR、NLR进行评估。采用Pearson相关、Wilcoxon符号秩、Mann-Whitney U和配对t检验评价各参数之间的关系。
结果：与治疗前相比，利妥昔单抗治疗6个月时CRP、ESR和DAS28-ESR水平显着降低。RA患者NLR和PLR比值高于对照组。在利妥昔单抗治疗6个月后，中位水平分别为33.5毫米/小时、5.7 mg/dL和3.7。水平低于基线治疗。治疗前后DAS28-ESR与NLR、DAS28-ESR和PLR有显着相关性。
结论：RA患者NLR和PLR均高于健康对照组，并且与DAS28-ESR相关。这些提示疾病活动性的指标在应用利妥昔单抗治疗后下降，并且与6个月时的疾病活动性相关。NLR和PLR可能是评价应用利妥昔单抗治疗的RA患者疾病活动性的有用指标。
附原文
Abstract
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may be used as indicators of inflammatory markers and disease activity due to inflammatory changes in neutrophils, platelets and lymphocytes. Our aim is to investigate the relationship between NLR, PLR ratio and disease activity in RA patients treated with rituximab.
METHODS: Thirty-eight patients (8 male, 30 female, mean age 56.8 ± 11.8 years) diagnosed with RA and 30 healthy controls were included in the study. Disease Activity Score of 28 joints - erythrocyte sedimentation rate (DAS28-ESR), lymphocyte, neutrophil, platelet counts, ESR, C-reactive protein (CRP), PLR, and NLRwere evaluated before and after rituximab in RA patients. The relationship between all parameters was assessed by Pearson"s correlation, Wilcoxon signed-rank, Mann-Whitney U and paired t tests.
RESULTS: The levels of CRP, ESR, and DAS28-ESR decreased significantly at 6 months of rituximab treatment compared to pre-treatment. NLR and PLR ratios were higher in patients with RA than the control group. The median levels were 33.5 mm/hour, 5.7 mg/dL, and 3.7 respectively after 6 months of rituximab treatment. And, the levels were lower than baseline treatment. There was a significant correlation between the levels of DAS28-ESR and NLR, DAS28-ESR and PLR before and after treatment.
CONCLUSIONS: The NLR and PLR were higher than healthy controls and correlated with DAS28-ESR in patients with RA. These parameters which are indicative of disease activity decrease with rituximab and correlate with disease activity at 6 months. The NLR and PLR may be useful indices to evaluate RA disease activity treated with rituximab.
引自：Sargin G, Senturk T, Yavasoglu I, Kose R. Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab. Int J Rheum Dis. Oct 18. doi: 10.1111/1756-185X.13400. [Epub ahead of print]
中性粒细胞与淋巴细胞比率（NLR）和血小板与淋巴细胞比率（PLR）与应用利妥昔单抗治疗的RA患者疾病活动度相关
